Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • Press releases
  • Investors & Media
    • Share information
    • Financial Reports
      • Annual reports
      • Interim reports
      • Year-end reports
    • Presentations
    • Media
      • Image library
      • Video library
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • Financial calendar
      • General meetings
  • Contact
    • Career
    • Business development
Skip to content
Regulatory
1 December 2022

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllAnnual reportInterim ReportNewsNewsletterPress releaseYear end reportRegulatory posts
1 December 2022 Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer Download Presentation Webcast Workbook
30 September 2022 Scandion Oncology announce topline results from part 2 of the CORIST phase II trial Download Presentation Webcast Workbook
31 August 2022 Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology Download Presentation Webcast Workbook
30 August 2022 Scandion Oncology announce change to its Executive Management Download Presentation Webcast Workbook
17 August 2022 Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101 Download Presentation Webcast Workbook
1 July 2022 Scandion Oncology announces preliminary outcome of its rights issue Download Presentation Webcast Workbook
1 June 2022 Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million Download Presentation Webcast Workbook
8 November 2021 PANTAX study read-out postponed Download Presentation Webcast Workbook
8 September 2021 Scandion Oncology provides a clear path to market for SCO-101 at today’s Capital Markets Day Download Presentation Webcast Workbook
7 September 2021 Scandion Oncology strengthens its Clinical Advisory Board with three new members Download Presentation Webcast Workbook
6 September 2021 Scandion Oncology receives approval for initiating the CORIST part 2 trial Download Presentation Webcast Workbook
2 September 2021 Positive Results from the Scandion Oncology A/S and Alligator Bioscience AB Collaboration Further Supports Efficacy of SCO-101 in Combination Therapy Download Presentation Webcast Workbook
  1. Frontpage

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

Investors & Media

  • Investors & Media
  • Share information
  • Financial Reports
  • Presentations
  • Media
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us


Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.